NAR Cancer最新文献_第6页

Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer. 对改变的系统结构分析揭示了癌症驱动突变的共同结构基础。

NAR Cancer Pub Date : 2023-01-18 eCollection Date: 2023-03-01 DOI: 10.1093/narcan/zcac040

Tomer Meirson, David Bomze, Ora Schueler-Furman, Salomon M Stemmer, Gal Markel

{"title":"Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer.","authors":"Tomer Meirson, David Bomze, Ora Schueler-Furman, Salomon M Stemmer, Gal Markel","doi":"10.1093/narcan/zcac040","DOIUrl":"10.1093/narcan/zcac040","url":null,"abstract":"A major effort in cancer research is to organize the complexities of the disease into fundamental traits. Despite conceptual progress in the last decades and the synthesis of hallmark features, no organizing principles governing cancer beyond cellular features exist. We analyzed experimentally determined structures harboring the most significant and prevalent driver missense mutations in human cancer, covering 73% (n = 168178) of the Catalog of Somatic Mutation in Cancer tumor samples (COSMIC). The results reveal that a single structural element-κ-helix (polyproline II helix)-lies at the core of driver point mutations, with significant enrichment in all major anatomical sites, suggesting that a small number of molecular traits are shared by most and perhaps all types of cancer. Thus, we uncovered the lowest possible level of organization at which carcinogenesis takes place at the protein level. This framework provides an initial scheme for a mechanistic understanding underlying the development of tumors and pinpoints key vulnerabilities.","PeriodicalId":18879,"journal":{"name":"NAR Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/06/73/zcac040.PMC9846427.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10635065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted zinc-finger repressors to the oncogenic HBZ gene inhibit adult T-cell leukemia (ATL) proliferation. 致癌基因 HBZ 的靶向锌指抑制因子可抑制成人 T 细胞白血病（ATL）的增殖。

NAR Cancer Pub Date : 2023-01-11 eCollection Date: 2023-03-01 DOI: 10.1093/narcan/zcac046

Tristan A Scott, Citradewi Soemardy, Roslyn M Ray, Kevin V Morris

{"title":"Targeted zinc-finger repressors to the oncogenic HBZ gene inhibit adult T-cell leukemia (ATL) proliferation.","authors":"Tristan A Scott, Citradewi Soemardy, Roslyn M Ray, Kevin V Morris","doi":"10.1093/narcan/zcac046","DOIUrl":"10.1093/narcan/zcac046","url":null,"abstract":"Human T-lymphotropic virus type I (HTLV-I) infects CD4+ T-cells resulting in a latent, life-long infection in patients. Crosstalk between oncogenic viral factors results in the transformation of the host cell into an aggressive cancer, adult T-cell leukemia/lymphoma (ATL). ATL has a poor prognosis with no currently available effective treatments, urging the development of novel therapeutic strategies. Recent evidence exploring those mechanisms contributing to ATL highlights the viral anti-sense gene HTLV-I bZIP factor (HBZ) as a tumor driver and a potential therapeutic target. In this work, a series of zinc-finger protein (ZFP) repressors were designed to target within the HTLV-I promoter that drives HBZ expression at highly conserved sites covering a wide range of HTLV-I genotypes. ZFPs were identified that potently suppressed HBZ expression and resulted in a significant reduction in the proliferation and viability of a patient-derived ATL cell line with the induction of cell cycle arrest and apoptosis. These data encourage the development of this novel ZFP strategy as a targeted modality to inhibit the molecular driver of ATL, a possible next-generation therapeutic for aggressive HTLV-I associated malignancies.","PeriodicalId":18879,"journal":{"name":"NAR Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/40/zcac046.PMC9832686.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10540509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe. 通过诱导复制灾难，ATR抑制克服了与ERCC1和p53缺陷相关的铂耐受性。

NAR Cancer Pub Date : 2023-01-11 eCollection Date: 2023-03-01 DOI: 10.1093/narcan/zcac045

Joshua R Heyza, Elmira Ekinci, Jacob Lindquist, Wen Lei, Christopher Yunker, Vilvanathan Vinothkumar, Rachelle Rowbotham, Lisa Polin, Natalie G Snider, Eric Van Buren, Donovan Watza, Jessica B Back, Wei Chen, Hirva Mamdani, Ann G Schwartz, John J Turchi, Gerold Bepler, Steve M Patrick

{"title":"ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe.","authors":"Joshua R Heyza, Elmira Ekinci, Jacob Lindquist, Wen Lei, Christopher Yunker, Vilvanathan Vinothkumar, Rachelle Rowbotham, Lisa Polin, Natalie G Snider, Eric Van Buren, Donovan Watza, Jessica B Back, Wei Chen, Hirva Mamdani, Ann G Schwartz, John J Turchi, Gerold Bepler, Steve M Patrick","doi":"10.1093/narcan/zcac045","DOIUrl":"10.1093/narcan/zcac045","url":null,"abstract":"ERCC1/XPF is a heterodimeric DNA endonuclease critical for repair of certain chemotherapeutic agents. We recently identified that ERCC1- and p53-deficient lung cancer cells are tolerant to platinum-based chemotherapy. ATR inhibition synergistically re-stored platinum sensitivity to platinum tolerant ERCC1-deficient cells. Mechanistically we show this effect is reliant upon several functions of ATR including replication fork protection and altered cell cycle checkpoints. Utilizing an inhibitor of replication protein A (RPA), we further demonstrate that replication fork protection and RPA availability are critical for platinum-based drug tolerance. Dual treatment led to increased formation of DNA double strand breaks and was associated with chromosome pulverization. Combination treatment was also associated with increased micronuclei formation which were capable of being bound by the innate immunomodulatory factor, cGAS, suggesting that combination platinum and ATR inhibition may also enhance response to immunotherapy in ERCC1-deficient tumors. In vivo studies demonstrate a significant effect on tumor growth delay with combination therapy compared with single agent treatment. Results of this study have led to the identification of a feasible therapeutic strategy combining ATR inhibition with platinum and potentially immune checkpoint blockade inhibitors to overcome platinum tolerance in ERCC1-deficient, p53-mutant lung cancers.","PeriodicalId":18879,"journal":{"name":"NAR Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/30/01/zcac045.PMC9832712.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10632187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered Runx1 splicing. 异质核核糖核蛋白K在急性髓性白血病中过度表达，并通过改变Runx1剪接引起小鼠骨髓增殖。

NAR Cancer Pub Date : 2022-12-09 eCollection Date: 2022-12-01 DOI: 10.1093/narcan/zcac039

Marisa J L Aitken, Prerna Malaney, Xiaorui Zhang, Shelley M Herbrich, Lauren Chan, Oscar Benitez, Ashley G Rodriguez, Huaxian Ma, Rodrigo Jacamo, Ruizhi Duan, Todd M Link, Steven M Kornblau, Rashmi Kanagal-Shamanna, Carlos E Bueso-Ramos, Sean M Post

{"title":"Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered Runx1 splicing.","authors":"Marisa J L Aitken, Prerna Malaney, Xiaorui Zhang, Shelley M Herbrich, Lauren Chan, Oscar Benitez, Ashley G Rodriguez, Huaxian Ma, Rodrigo Jacamo, Ruizhi Duan, Todd M Link, Steven M Kornblau, Rashmi Kanagal-Shamanna, Carlos E Bueso-Ramos, Sean M Post","doi":"10.1093/narcan/zcac039","DOIUrl":"10.1093/narcan/zcac039","url":null,"abstract":"Acute myeloid leukemia (AML) is driven by numerous molecular events that contribute to disease progression. Herein, we identify hnRNP K overexpression as a recurrent abnormality in AML that negatively correlates with patient survival. Overexpression of hnRNP K in murine fetal liver cells results in altered self-renewal and differentiation potential. Further, murine transplantation models reveal that hnRNP K overexpression results in myeloproliferation in vivo. Mechanistic studies expose a direct functional relationship between hnRNP K and RUNX1-a master transcriptional regulator of hematopoiesis often dysregulated in leukemia. Molecular analyses show that overexpression of hnRNP K results in an enrichment of an alternatively spliced isoform of RUNX1 lacking exon 4. Our work establishes hnRNP K's oncogenic potential in influencing myelogenesis through its regulation of RUNX1 splicing and subsequent transcriptional activity.","PeriodicalId":18879,"journal":{"name":"NAR Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/47/zcac039.PMC9732523.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-cell CRISPR immune screens reveal immunological roles of tumor intrinsic factors. 单细胞 CRISPR 免疫筛选揭示了肿瘤内在因子的免疫学作用。

NAR Cancer Pub Date : 2022-12-09 eCollection Date: 2022-12-01 DOI: 10.1093/narcan/zcac038

Jiakai Hou, Shaoheng Liang, Chunyu Xu, Yanjun Wei, Yunfei Wang, Yukun Tan, Nidhi Sahni, Daniel J McGrail, Chantale Bernatchez, Michael Davies, Yumei Li, Rui Chen, S Stephen Yi, Yiwen Chen, Cassian Yee, Ken Chen, Weiyi Peng

{"title":"Single-cell CRISPR immune screens reveal immunological roles of tumor intrinsic factors.","authors":"Jiakai Hou, Shaoheng Liang, Chunyu Xu, Yanjun Wei, Yunfei Wang, Yukun Tan, Nidhi Sahni, Daniel J McGrail, Chantale Bernatchez, Michael Davies, Yumei Li, Rui Chen, S Stephen Yi, Yiwen Chen, Cassian Yee, Ken Chen, Weiyi Peng","doi":"10.1093/narcan/zcac038","DOIUrl":"10.1093/narcan/zcac038","url":null,"abstract":"Genetic screens are widely exploited to develop novel therapeutic approaches for cancer treatment. With recent advances in single-cell technology, single-cell CRISPR screen (scCRISPR) platforms provide opportunities for target validation and mechanistic studies in a high-throughput manner. Here, we aim to establish scCRISPR platforms which are suitable for immune-related screens involving multiple cell types. We integrated two scCRISPR platforms, namely Perturb-seq and CROP-seq, with both in vitro and in vivo immune screens. By leveraging previously generated resources, we optimized experimental conditions and data analysis pipelines to achieve better consistency between results from high-throughput and individual validations. Furthermore, we evaluated the performance of scCRISPR immune screens in determining underlying mechanisms of tumor intrinsic immune regulation. Our results showed that scCRISPR platforms can simultaneously characterize gene expression profiles and perturbation effects present in individual cells in different immune screen conditions. Results from scCRISPR immune screens also predict transcriptional phenotype associated with clinical responses to cancer immunotherapy. More importantly, scCRISPR screen platforms reveal the interactive relationship between targeting tumor intrinsic factors and T cell-mediated antitumor immune response which cannot be easily assessed by bulk RNA-seq. Collectively, scCRISPR immune screens provide scalable and reliable platforms to elucidate molecular determinants of tumor immune resistance.","PeriodicalId":18879,"journal":{"name":"NAR Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10622444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The DNA repair function of BCL11A suppresses senescence and promotes continued proliferation of triple-negative breast cancer cells. BCL11A的DNA修复功能抑制衰老，促进三阴性乳腺癌细胞的持续增殖。

NAR Cancer Pub Date : 2022-12-01 DOI: 10.1093/narcan/zcac028

Elise Vickridge, Camila C F Faraco, Payman S Tehrani, Zubaidah M Ramdzan, Hedyeh Rahimian, Lam Leduy, Anne-Claude Gingras, Alain Nepveu

{"title":"The DNA repair function of BCL11A suppresses senescence and promotes continued proliferation of triple-negative breast cancer cells.","authors":"Elise Vickridge, Camila C F Faraco, Payman S Tehrani, Zubaidah M Ramdzan, Hedyeh Rahimian, Lam Leduy, Anne-Claude Gingras, Alain Nepveu","doi":"10.1093/narcan/zcac028","DOIUrl":"https://doi.org/10.1093/narcan/zcac028","url":null,"abstract":"We identified the BCL11A protein in a proximity-dependent biotinylation screen performed with the DNA glycosylase NTHL1. In vitro, DNA repair assays demonstrate that both BCL11A and a small recombinant BCL11A160-520 protein that is devoid of DNA binding and transcription regulatory domains can stimulate the enzymatic activities of two base excision repair enzymes: NTHL1 and DNA Pol β. Increased DNA repair efficiency, in particular of the base excision repair pathway, is essential for many cancer cells to proliferate in the presence of elevated reactive oxygen species (ROS) produced by cancer-associated metabolic changes. BCL11A is highly expressed in triple-negative breast cancers (TNBC) where its knockdown was reported to reduce clonogenicity and cause tumour regression. We show that BCL11A knockdown in TNBC cells delays repair of oxidative DNA damage, increases the number of oxidized bases and abasic sites in genomic DNA, slows down proliferation and induces cellular senescence. These phenotypes are rescued by ectopic expression of the short BCL11A160-520 protein. We further show that the BCL11A160-520 protein accelerates the repair of oxidative DNA damage and cooperates with RAS in cell transformation assays, thereby enabling cells to avoid senescence and continue to proliferate in the presence of high ROS levels.","PeriodicalId":18879,"journal":{"name":"NAR Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/a5/zcac028.PMC9516615.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9226125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

A convergent malignant phenotype in B-cell acute lymphoblastic leukemia involving the splicing factor SRRM1. 涉及剪接因子SRRM1的b细胞急性淋巴细胞白血病的会聚性恶性表型。

NAR Cancer Pub Date : 2022-12-01 DOI: 10.1093/narcan/zcac041

Adria Closa, Marina Reixachs-Solé, Antonio C Fuentes-Fayos, Katharina E Hayer, Juan L Melero, Fabienne R S Adriaanse, Romy S Bos, Manuel Torres-Diz, Stephen P Hunger, Kathryn G Roberts, Charles G Mullighan, Ronald W Stam, Andrei Thomas-Tikhonenko, Justo P Castaño, Raúl M Luque, Eduardo Eyras

{"title":"A convergent malignant phenotype in B-cell acute lymphoblastic leukemia involving the splicing factor SRRM1.","authors":"Adria Closa, Marina Reixachs-Solé, Antonio C Fuentes-Fayos, Katharina E Hayer, Juan L Melero, Fabienne R S Adriaanse, Romy S Bos, Manuel Torres-Diz, Stephen P Hunger, Kathryn G Roberts, Charles G Mullighan, Ronald W Stam, Andrei Thomas-Tikhonenko, Justo P Castaño, Raúl M Luque, Eduardo Eyras","doi":"10.1093/narcan/zcac041","DOIUrl":"https://doi.org/10.1093/narcan/zcac041","url":null,"abstract":"A significant proportion of infant B-cell acute lymphoblastic leukemia (B-ALL) patients remains with a dismal prognosis due to yet undetermined mechanisms. We performed a comprehensive multicohort analysis of gene expression, gene fusions, and RNA splicing alterations to uncover molecular signatures potentially linked to the observed poor outcome. We identified 87 fusions with significant allele frequency across patients and shared functional impacts, suggesting common mechanisms across fusions. We further identified a gene expression signature that predicts high risk independently of the gene fusion background and includes the upregulation of the splicing factor SRRM1. Experiments in B-ALL cell lines provided further evidence for the role of SRRM1 on cell survival, proliferation, and invasion. Supplementary analysis revealed that SRRM1 potentially modulates splicing events associated with poor outcomes through protein-protein interactions with other splicing factors. Our findings reveal a potential convergent mechanism of aberrant RNA processing that sustains a malignant phenotype independently of the underlying gene fusion and that could potentially complement current clinical strategies in infant B-ALL.","PeriodicalId":18879,"journal":{"name":"NAR Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pancan-MNVQTLdb: systematic identification of multi-nucleotide variant quantitative trait loci in 33 cancer types. panan - mnvqtldb: 33种癌症多核苷酸变异数量性状位点的系统鉴定。

NAR Cancer Pub Date : 2022-12-01 DOI: 10.1093/narcan/zcac043

Dongyang Wang, Wen Cao, Wenqian Yang, Weiwei Jin, Haohui Luo, Xiaohui Niu, Jing Gong

{"title":"Pancan-MNVQTLdb: systematic identification of multi-nucleotide variant quantitative trait loci in 33 cancer types.","authors":"Dongyang Wang, Wen Cao, Wenqian Yang, Weiwei Jin, Haohui Luo, Xiaohui Niu, Jing Gong","doi":"10.1093/narcan/zcac043","DOIUrl":"https://doi.org/10.1093/narcan/zcac043","url":null,"abstract":"Multi-nucleotide variants (MNVs) are defined as clusters of two or more nearby variants existing on the same haplotype in an individual. Recent studies have identified millions of MNVs in human populations, but their functions remain largely unknown. Numerous studies have demonstrated that single-nucleotide variants could serve as quantitative trait loci (QTLs) by affecting molecular phenotypes. Therefore, we propose that MNVs can also affect molecular phenotypes by influencing regulatory elements. Using the genotype data from The Cancer Genome Atlas (TCGA), we first identified 223 759 unique MNVs in 33 cancer types. Then, to decipher the functions of these MNVs, we investigated the associations between MNVs and six molecular phenotypes, including coding gene expression, miRNA expression, lncRNA expression, alternative splicing, DNA methylation and alternative polyadenylation. As a result, we identified 1 397 821 cis-MNVQTLs and 402 381 trans-MNVQTLs. We further performed survival analysis and identified 46 173 MNVQTLs associated with patient overall survival. We also linked the MNVQTLs to genome-wide association studies (GWAS) data and identified 119 762 MNVQTLs that overlap with existing GWAS loci. Finally, we developed Pancan-MNVQTLdb (http://gong_lab.hzau.edu.cn/mnvQTLdb/) for data retrieval and download. Pancan-MNVQTLdb will help decipher the functions of MNVs in different cancer types and be an important resource for genetic and cancer research.","PeriodicalId":18879,"journal":{"name":"NAR Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/73/74/zcac043.PMC9773367.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10803502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress. UBE2T通过抑制DNA复制应激促进乳腺癌肿瘤生长。

NAR Cancer Pub Date : 2022-12-01 DOI: 10.1093/narcan/zcac035

Roshan Dutta, Praveen Guruvaiah, Kiran Kumar Reddi, Suresh Bugide, Dhana Sekhar Reddy Bandi, Yvonne J K Edwards, Kamaljeet Singh, Romi Gupta

{"title":"UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress.","authors":"Roshan Dutta, Praveen Guruvaiah, Kiran Kumar Reddi, Suresh Bugide, Dhana Sekhar Reddy Bandi, Yvonne J K Edwards, Kamaljeet Singh, Romi Gupta","doi":"10.1093/narcan/zcac035","DOIUrl":"https://doi.org/10.1093/narcan/zcac035","url":null,"abstract":"Breast cancer is a leading cause of cancer-related deaths among women, and current therapies benefit only a subset of these patients. Here, we show that ubiquitin-conjugating enzyme E2T (UBE2T) is overexpressed in patient-derived breast cancer samples, and UBE2T overexpression predicts poor prognosis. We demonstrate that the transcription factor AP-2 alpha (TFAP2A) is necessary for the overexpression of UBE2T in breast cancer cells, and UBE2T inhibition suppresses breast cancer tumor growth in cell culture and in mice. RNA sequencing analysis identified interferon alpha-inducible protein 6 (IFI6) as a key downstream mediator of UBE2T function in breast cancer cells. Consistently, UBE2T inhibition downregulated IFI6 expression, promoting DNA replication stress, cell cycle arrest, and apoptosis and suppressing breast cancer cell growth. Breast cancer cells with IFI6 inhibition displayed similar phenotypes as those with UBE2T inhibition, and ectopic IFI6 expression in UBE2T-knockdown breast cancer cells prevented DNA replication stress and apoptosis and partly restored breast cancer cell growth. Furthermore, UBE2T inhibition enhanced the growth-suppressive effects of DNA replication stress inducers. Taken together, our study identifies UBE2T as a facilitator of breast cancer tumor growth and provide a rationale for targeting UBE2T for breast cancer therapies.","PeriodicalId":18879,"journal":{"name":"NAR Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10256277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment. PARP1抑制剂耐药机制及其对癌症治疗的意义。

NAR Cancer Pub Date : 2022-12-01 DOI: 10.1093/narcan/zcac042

Lindsey M Jackson, George-Lucian Moldovan

引用次数: 7